BostonGene Announces Acceptance of Eight Abstracts to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2021

WALTHAM, Mass.--(BUSINESS WIRE)-- BostonGene Corporation, a biomedical software company committed to defining optimal precision medicine-based therapies for cancer patients, today announced that eight abstracts were selected for poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021, which will be conducted virtually from April 10 - 15, 2021 and May 17 - 21, 2021.

The presentations underscore the importance of the application of novel and cutting-edge analytical tools to improve the diagnosis and treatment for cancer patients. These tools were applied across a wide range of cancers to further understand tumor biology and identify biomarkers for diverse therapies in an effort to propel precision medicine to the forefront of clinical decision making.

"We are proud to present at the AACR Annual Meeting. These results demonstrate BostonGene's unique ability to identify novel and personalized treatment options through next generation multi-platform analytics, further advancing and optimizing outcomes for each cancer patient," said Nathan Fowler, MD, Chief Medical Officer at BostonGene.

Details of the poster presentations are below:

Title: AI-driven multifaceted predictive biomarkers of response to tyrosine kinase inhibition and immune checkpoint blockade in clear cell renal cell carcinoma
Session:PO.CL06.06 - Immune Response to Therapies
Poster: 516
Presenter:Natalia Miheecheva, MSc,BostonGene

Research conducted withWashington University School of Medicine in St Louis.

Title: Association of circulating myeloid derived suppressor cells with systemic lymphopenia following chemoradiotherapy in glioblastoma
Session:PO.CL06.04 - Immune Mechanisms Invoked by Therapies Poster: 507
Presenter: Dinesh Thotala, PhD, Washington University School of Medicine in St Louis

Research conducted withWashington University School of Medicine in St Louis.

Title: Astraea: A first-in-class biomarker database integrating genomic, transcriptomic, and tumor microenvironment properties for precision oncology
Session:PO.BSB01.03 - Database Resources
Poster: 205
Presenter: Azamat Gafurov, MSc,BostonGene

Title: Evaluating the clinical utility of RNA-seq-based PD-L1 expression and cellular deconvolution as alternatives to conventional immunohistochemistry in clear cell renal cell carcinoma
Session:PO.BSB01.02 - Application of Bioinformatics to Cancer Biology
Poster: 161
Presenter: Natalia Miheecheva, MSc, BostonGene

Research conducted withWashington University School of Medicine in St Louis.

Title: Integrated multiregional transcriptomic and multi-parameter single-cell imaging analysis of clear cell renal cell carcinoma elucidates diverse cellular communities present within the tumor microenvironment
Session:PO.TB06.04 - Immune Cells in the Tumor Microenvironment
Poster: 2742
Presenter: Natalia Miheecheva, MSc,BostonGene

Research conducted withWashington University School of Medicine in St Louis.

Title: MutAnt: Mutation annotation machine learning algorithm for pathogenicity evaluation of single nonsynonymous nucleotide substitutions in cancer cells
Session: PO.BSB02.01 - Artificial Intelligence and Machine Learning
Poster: 192
Presenter: Aleksandr Sarachakov, MSc, BostonGene

Title: Predictors of treatment responses in a preoperative window of opportunity trial of nivolumab in resectable squamous cell carcinoma of the head and neck
Session: PO.ET02.03 - Role of the Microenvironment in Therapeutic Response
Poster: 1441
Presenter: Nikita Kotlov, MSc, BostonGene

Research conducted withThomas Jefferson University.

Title: Tumor immune microenvironment based molecular functional clustering reveals a prognostic signature that predicts overall survival in patients with gastric cancer
Session:PO.TB06.08 - Tumor Immune System Interactions
Poster: 3182
Presenter: Prashant V. Thakkar, Weill Cornell Medicine

Research conducted withWeill Cornell Medicine.

The e-poster website will be launched Saturday, April 10, 2021, the first day of the AACR Virtual Annual Meeting. All e-posters will be made available for browsing on the AACR Annual Meeting website on this date.

Additionally, the abstracts will be published in an online-only Proceedings supplement to the AACR journal Cancer Research after the completion of the AACR Virtual Annual Meeting.

About BostonGene Corporation

BostonGene Corporation is pioneering the use of biomedical software for advanced patient analysis and personalized therapy decision making in the fight against cancer. BostonGene's unique solution performs sophisticated analytics to aid clinicians in their evaluation of viable treatment options for each patient's individual genetics, tumor and tumor microenvironment, clinical characteristics and disease profile. BostonGene's mission is to enable physicians to provide every patient with the highest probability of survival through optimal cancer treatments using advanced, personalized therapies. For more information, visit BostonGene at http://www.BostonGene.com.

 

BostonGene
Erin O'Reilly
+1-781-366-7049
Erin.Oreilly@BostonGene.com

 

Source: BostonGene Corporation

Did you like this article?